March 04, 2016 12:59 PM Eastern Standard Time
PRINCETON, N.J. & PARIS--(BUSINESS WIRE)--Regulatory News:
STENTYS (the « Company » — STNT – FR0010949404) (Paris:STNT), announces the successful completion of its capital increase with preemptive rights opened for subscription from February 15, 2016 to February 26, 2016.
The final gross proceeds of the transaction amount to €12,648,919.50, corresponding to the issuance of 5,621,742 new shares.
Total demand for this capital increase amounted to approximately €9.1M, i.e. a subscription rate of approximately of 72.23%:
- 3,695,526 new shares were subscribed on an irreducible basis ("à titre irréductible"), representing approximately 65.74% of the number of new shares to be issued.
- Orders subject to reduction ("à titre réductible") amounted to 364,815 new shares and will, as a result, be fully allocated.
Investors who had committed to purchase the remaining shares not subscribed after the subscription period have been allocated in proportion to their commitment a number of 1,561,401 new shares by the Company's Board of Directors.
The Company's share capital, following the capital increase, will amount to €534,065.70, represented by 17,802,190 shares with a par value of €0.03 each.
The proceeds of this issue will enable STENTYS to continue its development and its geographic expansion, firstly in European centers by extending its network of distributors and, secondly, through obtaining approvals in countries outside of the CE Marking (initially in Russia and India, then in Brazil, China, Korea and Japan).
STENTYS also intends to strengthen its position in France1, one of the main European markets, and will use part of the funds raised to finance two clinical studies in order to obtain the reimbursement of the stent Xposition S:
- GAIN, a randomized study comparing Xposition S to a conventional drug-eluting stent already reimbursed in France. This study would enroll 300 patients from 30 European centers (including a minimum of 5 in France). The endpoints of the study would be the artery diameter narrowing at 9 months (Late Lumen Loss), as measured by angiography, and major adverse cardiac events.
- WIN, a study designed to complement the randomized GAIN study in assessing the safety and the performance of the Xposition S stent in routine clinical practice. WIN would recruit 760 patients in 30 sites across Europe (with a minimum of 5 sites in France). Patient follow up would be after a 12 months period.
In addition, the proceeds of the transaction will also finance a clinical study to evaluate the efficacy of the Xposition S stent in treating lesions of the Left Main (main artery of the human heart) with a study enrolling 200 patients treated with Xposition S and recruited from 20 European clinical sites. The primary endpoint would be the rate of major adverse cardiac events at 12 months.
Gonzague Issenmann, CEO and co-founder of STENTYS, commented: "We are delighted by the follow on from our shareholders to this capital increase, despite volatile financial markets. I would like to thank them for their support. This fund raising is building solid financial foundations for STENTYS and allows the company to continue its growth strategy, in France and worldwide."
The settlement and delivery and the listing of the new shares on the regulated market of Euronext in Paris are expected to take place on March 8, 2016. The new shares will carry full dividend entitlement and will be traded on the same trading line as STENTYS' existing shares under the same ISIN code FR0010949404.
Société Générale Corporate & Investment Banking is acting as Lead Manager and Sole Bookrunner of the issue.
Information available to the public
The prospectus, filed with the French financial markets authority (Autorité des marchés financiers - "AMF") under number 16-045, dated February 11, 2016 consisting of the registration document (the "Registration Document") of STENTYS registered with the AMF on July 29, 2015 under number D.15-0807, the update to the Registration Document of STENTYS filed with the AMF on February 11, 2016 under number D.15-0807-A01 (the "Registration Document Update"), a securities note (the "Securities Note") including the summary of the prospectus may be obtained free of charge from STENTYS's registered office (29-31 Rue Saint-Augustin, 75002 Paris) and is also available on STENTYS' website (www.stentys.com) and the AMF's website (www.amf-france.org).
STENTYS draws investors' attention to the risk factors described in chapter 4 of the Registration Document as updated in section 4.1 of the Registration Document Update, as well as in section 2 of the Securities Note.
FY 2015 Results, on March 16, 2016
STENTYS is developing and commercializing innovative solutions for the treatment of patients with complex coronary artery disease. STENTYS' Self-Apposing® Stents are designed to adapt to vessels with ambiguous or fluctuating diameters in order to prevent the malapposition problems associated with conventional stents. The APPOSITION clinical trials in the treatment of acute myocardial infarction showed a very low one year mortality rate and a faster arterial healing compared to conventional stents. The company's product portfolio also includes MiStent SES®, a coronary DES whose new drug delivery mechanism is designed to match vessel response, and is marketed through STENTYS' commercial network in Europe, Middle East, Asia and Latin America. More information on www.stentys.com.
1 In France, drug-eluting stents (or "Drug Eluting Stent" - DES) represented about 75% of stents market in 2014 (source: Prof. Blanchard, High Tech Congress 2015).
STENTYS is listed on Comp. C of the Euronext Paris market
ISIN: FR0010949404 – Ticker: STNT